Dismissal Of Teva Suit Triggered Ticlopidine 180-Days, Appeals Court Rules

Torpharm's 180-day ticlopidine exclusivity was triggered by the June 1998 dismissal of Teva's declaratory judgment action against Roche in California federal court, the D.C. federal appeals court ruled July 20.